Application of sodium valproate in preparation of drug for treating human coronavirus infected pneumonia

A technology of sodium valproate and coronavirus, applied in antiviral agents, drug combinations, active ingredients of anhydride/acid/halide, etc.

Pending Publication Date: 2020-09-18
ACADEMY OF MILITARY MEDICAL SCI
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In view of the current lack of effective drugs for the treatment and/or prevention of respiratory viruses, especially novel coronavirus infections that cause primary and/or secondary lung infections and/or respiratory distress, the purpos

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sodium valproate in preparation of drug for treating human coronavirus infected pneumonia
  • Application of sodium valproate in preparation of drug for treating human coronavirus infected pneumonia
  • Application of sodium valproate in preparation of drug for treating human coronavirus infected pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1.VPA is to the protective effect of coronavirus (xCOV) infected cell

[0034] In this example, the coronavirus xCOV infection Vero cell model isolated and cultured from pangolins is used to evaluate the protective effect of VPA on coronavirus-infected cells, and then to explore the possibility of VPA being used to prepare anti-coronavirus, especially SARS-CoV-2 infection treatment drugs sex.

[0035] 1.1 Experimental scheme:

[0036] 1.1.1 Cell line: Vero cells

[0037] 1.1.2 Virus: Coronavirus xCOV isolated and cultured from pangolins (this virus is not pathogenic to humans and can be cultivated in ordinary laboratories, and the relationship between this virus and SARS-CoV-2 is much better than that of SARS virus, Therefore can be used as the antiviral drug screening model of ideal SARS-CoV-2), this virus does not infect people, is safe and reliable.

[0038] 1.1.3 Protection experiment of VPA on coronavirus (xCOV) infected cells: Dilute the dry drug pow...

Embodiment 2

[0042] Embodiment 2.VPA is to the treatment experiment of human coronavirus 229E mouse pneumonia model

[0043] In this example, the pneumonia model of BALB / c mice infected with human coronavirus 229E was used to evaluate the therapeutic effect of VPA on coronavirus-infected pneumonia, and then to explore the possibility of VPA being used to prepare anti-coronavirus lung infection treatment drugs.

[0044] 2.1 Experimental scheme

[0045] 2.1.1 Drugs: The positive drug is chloroquine phosphate tablets, and the tested drug is VPA.

[0046] 2.1.2 Experimental animals

[0047]

[0048] 2.1.3 Virus strains and cells

[0049] 2.1.3.1 Virus strain: human coronavirus 229E (HCoV-229E), stored in -80°C refrigerator for later use.

[0050] 2.1.3.2 Cell line: human embryonic lung fibroblast MRC5, stored in liquid nitrogen for future use.

[0051] 2.1.4 Evaluation of the therapeutic effect of VPA on human coronavirus 229E mouse pneumonia model:

[0052] 2.1.4.1 Drug configuration ...

Embodiment 3

[0071] Example 3. The protective effect of VPA on human novel coronavirus (SARS-CoV-2) infected cells

[0072]In this example, the Vero cell model infected with novel coronavirus isolates was used to evaluate the inhibitory effect of VPA on novel coronavirus infection, and to determine the possibility of VPA being used to prepare anti-coronavirus, especially novel coronavirus infection treatment drugs.

[0073] 3.1 Experimental scheme

[0074] 3.1.1 Cell line: Vero cells

[0075] 3.1.2 Viruses: Novel coronavirus isolates.

[0076] 3.1.3 Pharmacodynamic evaluation experiment of VPA against novel coronavirus: spread Vero cells in a 48-well plate, repeat in three wells, add 12.5ug / ml concentration of drug (100 μl / well) and inoculate novel coronavirus (MOI= 0.01), and the control group was inoculated with novel coronavirus (MOI=0.01) without adding VPA drugs. 37°C 5% CO after virus inoculation 2 After incubation, the cytopathic changes were examined under the microscope after ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of sodium valproate (VPA) in preparation of a drug for treating respiratory tract virus infectious diseases, and a pharmaceutical preparation containing the VPAand prepared according to the application. The preparation has remarkable prevention and treatment effects on primary and/or secondary pulmonary infection caused by infection of respiratory tract virus including novel coronavirus.

Description

technical field [0001] The invention discloses a medical application of a compound and belongs to the field of pharmaceutical products. Background technique [0002] Virus is a kind of pathogenic microorganism composed of nucleic acid and protein, without typical cell structure, parasitic in living cells and multiplying by replication. Clinical data show that among the infectious diseases, the diseases caused by virus infection account for more than 75% of the total, among which respiratory virus infection is the most common. There are many viruses that can cause respiratory virus infection, among which coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, rhinovirus or adenovirus are the most common. At present, the treatment of viral respiratory tract infection is still mainly symptomatic, and there is still a lack of ideal and reliable preventive means and treatment options. [0003] Coronaviruses (Coronaviruses, CoV) can cause a variety of dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/19A61P31/14A61P11/00A61P31/16
CPCA61K31/19A61P31/14A61P11/00A61P31/16Y02A50/30
Inventor 于群蒋兴伟任素萍安华英柏杉杉高锋华李宝义张猛
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap